{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:12:58Z","timestamp":1745467978021,"version":"3.40.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"5-6","license":[{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,23]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>The prevalence of treatment-resistant depression within global and military populations highlights the need for novel treatment approaches beyond monoamine neurotransmitter modulators. Buprenorphine (BUP), a semi-synthetic partial opioid agonist, is approved for the treatment of opioid use disorder and has shown promise in treating both depression and chronic pain. This case report discusses the use of transdermal BUP in treating a 36\u2009year-old man with treatment-resistant depression with prominent anhedonia, military-related posttraumatic stress disorder, and chronic pain because of barosinusitis. Significant reductions in anxious and depressive symptoms, including in anhedonia, were observed with lasting effects. An unexpected finding was the discontinuation of prescribed hydromorphone for pain, suggesting the potential unique benefit of BUP in treating chronic pain and treatment resistant depression comorbidities. These findings implicate the diverse beneficial potential of BUP in psychiatric treatments for military populations.<\/jats:p>","DOI":"10.1093\/milmed\/usae416","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T16:14:06Z","timestamp":1726676046000},"page":"e1314-e1317","source":"Crossref","is-referenced-by-count":0,"title":["Buprenorphine for the Treatment of Military-related PTSD With Treatment-resistant Depression and Unexpected Benefit for Chronic Pain: Case Report"],"prefix":"10.1093","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2883-9791","authenticated-orcid":false,"given":"Anna","family":"Skorzewska","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Western University , London, ON N6C 0A7,","place":["Canada"]},{"name":"Department of Psychiatry, University of Toronto, 250 College Street , Toronto, ON M5T 1R8,","place":["Canada"]},{"name":"Department of Psychiatry, St. Joseph\u2019s OSI Clinic, St. Joseph\u2019s Health Care London , London, ON N6A 4V2,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5171-2457","authenticated-orcid":false,"given":"William A","family":"Younger","sequence":"additional","affiliation":[{"name":"MacDonald Franklin OSI Research Centre, Lawson Health Research Institute , London, ON N6C 0A7,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8057-0617","authenticated-orcid":false,"given":"Kylie S","family":"Dempster","sequence":"additional","affiliation":[{"name":"MacDonald Franklin OSI Research Centre, Lawson Health Research Institute , London, ON N6C 0A7,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3288-7609","authenticated-orcid":false,"given":"Anthony","family":"Nazarov","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Western University , London, ON N6C 0A7,","place":["Canada"]},{"name":"Department of Psychiatry, St. Joseph\u2019s OSI Clinic, St. Joseph\u2019s Health Care London , London, ON N6A 4V2,","place":["Canada"]},{"name":"MacDonald Franklin OSI Research Centre, Lawson Health Research Institute , London, ON N6C 0A7,","place":["Canada"]},{"name":"Department of Psychiatry and Behavioural Neurosciences, McMaster University , Hamilton, ON L8N 3K7,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2927-6735","authenticated-orcid":false,"given":"J. Don","family":"Richardson","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Western University , London, ON N6C 0A7,","place":["Canada"]},{"name":"Department of Psychiatry, St. Joseph\u2019s OSI Clinic, St. Joseph\u2019s Health Care London , London, ON N6A 4V2,","place":["Canada"]},{"name":"MacDonald Franklin OSI Research Centre, Lawson Health Research Institute , London, ON N6C 0A7,","place":["Canada"]},{"name":"Department of Psychiatry and Behavioural Neurosciences, McMaster University , Hamilton, ON L8N 3K7,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,9,18]]},"reference":[{"issue":"2","key":"2025042308421530600_R1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1001\/jamapsychiatry.2022.3860","article-title":"Association of treatment-resistant depression with patient outcomes and health care resource utilization in a population-wide study","volume":"80","author":"Lundberg","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"2025042308421530600_R2","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-022-04184-8","article-title":"Epidemiology of treatment resistant depression among major depressive disorder patients in Israel","volume":"22","author":"Moser","year":"2022","journal-title":"BMC Psychiatry"},{"issue":"1","key":"2025042308421530600_R3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/hrp.0000000000000242","article-title":"Novel targets to treat depression: opioid-based therapeutics","volume":"28","author":"Browne","year":"2020","journal-title":"Harv Rev Psychiatry"},{"key":"2025042308421530600_R4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jad.2020.03.089","article-title":"A meta-analysis of the potential antidepressant effects of buprenorphine versus placebo as an adjunctive pharmacotherapy for treatment-resistant depression","volume":"271","author":"Dinoff","year":"2020","journal-title":"J Affect Disord"},{"issue":"6","key":"2025042308421530600_R5","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40263-019-00637-z","article-title":"Buprenorphine treatment for opioid use disorder: an overview","volume":"33","author":"Shulman","year":"2019","journal-title":"CNS Drugs"},{"issue":"2","key":"2025042308421530600_R6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2165\/00003495-197917020-00001","article-title":"Buprenorphine: a review of its pharmacological properties and therapeutic efficacy","volume":"17","author":"Heel","year":"1979","journal-title":"Drugs"},{"key":"2025042308421530600_R7","article-title":"Buprenorphine for chronic pain: review of the clinical effectiveness","volume-title":"Canadian Agency for Drugs and Technologies in Health","author":"Canadian Agency for Drugs and Technologies in Health","year":"2017"},{"issue":"3","key":"2025042308421530600_R8","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jpain.2023.09.014","article-title":"\u201cBuprenorphine, it works so differently\u201d: adults with sickle cell disease describe transitioning to buprenorphine for treatment of chronic pain","volume":"25","author":"Prince","year":"2023","journal-title":"J Pain"},{"issue":"2","key":"2025042308421530600_R9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1213\/ANE.0000000000002718","article-title":"Treatment of chronic pain with various buprenorphine formulations: a systematic review of clinical studies","volume":"127","author":"Aiyer","year":"2018","journal-title":"Anesthesia Analg"},{"author":"Weathers","key":"2025042308421530600_R10","article-title":"The PTSD checklist for DSM-5 (PCL5)"},{"issue":"9","key":"2025042308421530600_R11","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"issue":"10","key":"2025042308421530600_R12","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety dirsorder: the GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch Intern Med"},{"issue":"4","key":"2025042308421530600_R13","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1001\/archpsyc.1978.01770280111012","article-title":"Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction","volume":"35","author":"Jasinski","year":"1978","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"2025042308421530600_R14","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1017\/S0033291720000525","article-title":"Buprenorphine: prospective novel therapy for depression and PTSD","volume":"50","author":"Madison","year":"2020","journal-title":"Psychol Med"},{"key":"2025042308421530600_R15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.pharmthera.2019.04.009","article-title":"Targeting opioid dysregulation in depression for the development of novel therapeutics","volume":"201","author":"Browne","year":"2019","journal-title":"Pharmacol Ther"},{"issue":"1","key":"2025042308421530600_R16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1146\/annurev-pharmtox-010919-023317","article-title":"Kappa opioid receptor antagonists as potential therapeutics for stress-related disorders","volume":"60","author":"Jacobson","year":"2020","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2025042308421530600_R17","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104800","article-title":"The opioid system in depression","volume":"140","author":"Jelen","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"issue":"6","key":"2025042308421530600_R18","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/npp.2014.330","article-title":"Evaluation of opioid modulation in major depressive disorder","volume":"40","author":"Ehrich","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"2025042308421530600_R19","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1176\/appi.ajp.2015.15070921","article-title":"Opioid modulation with buprenorphine\/samidorphan as adjunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trial","volume":"173","author":"Fava","year":"2016","journal-title":"Am J Psychiatry"},{"issue":"8","key":"2025042308421530600_R20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19082410","article-title":"The efficacy of buprenorphine in major depression, treatment-resistant depression and suicidal behavior: a systematic review","volume":"19","author":"Serafini","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2025042308421530600_R21","doi-asserted-by":"publisher","DOI":"10.3389\/adar.2022.10254","article-title":"Buprenorphine as a treatment for major depression and opioid use disorder","volume":"2","author":"Namchuk","year":"2022","journal-title":"Adv Drug Alcohol Res"},{"issue":"8","key":"2025042308421530600_R22","doi-asserted-by":"publisher","first-page":"e785","DOI":"10.4088\/JCP.13m08725","article-title":"Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults","volume":"75","author":"Karp","year":"2014","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"2025042308421530600_R23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.bpsgos.2021.09.003","article-title":"Low-dose augmentation with buprenorphine for treatment-resistant depression: a multisite randomized controlled trial with multimodal assessment of target engagement","volume":"2","author":"Lee","year":"2022","journal-title":"Biol Psychiatry Glob Open Sci"},{"issue":"4","key":"2025042308421530600_R24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.9740\/mhc.2018.07.175","article-title":"Kappa opioid receptor antagonism: are opioids the answer for treatment resistant depression?","volume":"8","author":"Peckham","year":"2018","journal-title":"Mental Health Clinician"},{"issue":"2","key":"2025042308421530600_R25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.12740\/PP\/102658","article-title":"The use of buprenorphine in the treatment of drug-resistant depression - an overview of the studies","volume":"54","author":"Stefanowski","year":"2020","journal-title":"Psychiatr Pol"},{"key":"2025042308421530600_R26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ajp.2017.01.015","article-title":"Use of buprenorphine in treatment of refractory depression\u2014a review of current literature","volume":"26","author":"Stanciu","year":"2017","journal-title":"Asian J Psychiatr"},{"issue":"3","key":"2025042308421530600_R27","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jpainsymman.2004.07.005","article-title":"Buprenorphine: considerations for pain management","volume":"29","author":"Johnson","year":"2005","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"2025042308421530600_R28","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/adb.12163","article-title":"Abuse potential of intranasal buprenorphine versus buprenorphine\/naloxone in buprenorphine-maintained heroin users","volume":"20","author":"Jones","year":"2015","journal-title":"Addict Biol"},{"issue":"1","key":"2025042308421530600_R29","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2147\/tcrm.s12160400","article-title":"Transdermal buprenorphine in the management of persistent pain\u2014safety aspects","volume":"2","author":"Likar","year":"2006","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"2025042308421530600_R30","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/jcph.1280","article-title":"Abuse potential of buprenorphine\/samidorphan combination compared to buprenorphine and placebo: a phase 1 randomized controlled trial","volume":"59","author":"Pathak","year":"2019","journal-title":"J Clin Pharmacol"}],"container-title":["Military Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/milmed\/article-pdf\/190\/5-6\/e1314\/59183210\/usae416.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/milmed\/article-pdf\/190\/5-6\/e1314\/59183210\/usae416.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T12:42:24Z","timestamp":1745412144000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/milmed\/article\/190\/5-6\/e1314\/7760197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,18]]},"references-count":30,"journal-issue":{"issue":"5-6","published-online":{"date-parts":[[2024,9,18]]},"published-print":{"date-parts":[[2025,4,23]]}},"URL":"https:\/\/doi.org\/10.1093\/milmed\/usae416","relation":{},"ISSN":["0026-4075","1930-613X"],"issn-type":[{"type":"print","value":"0026-4075"},{"type":"electronic","value":"1930-613X"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2024,9,18]]}}}